<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Transformation of Philadelphia (Ph)-negative myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MPNs) to <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) is associated with poor response to chemotherapy and short survival </plain></SENT>
<SENT sid="1" pm="."><plain>Fifty-four patients with Ph-negative MPN (including 21 essential <z:e sem="disease" ids="C0836924" disease_type="Disease or Syndrome" abbrv="">thrombocythemia</z:e> [ET], 21 <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>], 7 primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>, and 5 unclassified MPN) who had progressed to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (n = 26) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (n = 28) were treated with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> in a patient-named program </plain></SENT>
<SENT sid="2" pm="."><plain>Overall response rate was 52% (24% complete response [CR], 11% partial response [PR], 8% marrow CR or CR with incomplete recovery of cytopenias, 9% hematologic improvement) and median response duration was 9 months </plain></SENT>
<SENT sid="3" pm="."><plain>Prognostic factors were for overall response the underlying MPN (71% vs 33% responses in ET and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>, respectively; P = .016); prognostic factors for CR achievement were the underlying MPN (14% CR for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> vs 43% for ET; P = .040) and World Health Organization classification at transformation (36% vs 12% CR in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, respectively, P = .038) </plain></SENT>
<SENT sid="4" pm="."><plain>Recurrence of <z:hpo ids='HP_0011010'>chronic</z:hpo> phase features of the initial MPN was observed in 39% of the responders </plain></SENT>
<SENT sid="5" pm="."><plain>Median overall survival was 11 months </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> gives encouraging results in Ph-negative MPN having progressed to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, but response duration is short, and consolidation treatments have to be evaluated </plain></SENT>
</text></document>